Enovis director Angela Lalor buys $49,386 in company stock
Enovis director Angela Lalor recently purchased $49,386 worth of company stock through open market transactions on November 12 and 13, 2026, acquiring a total of 1,754 shares. These purchases increase her direct holdings to 34,997 shares. The stock is currently trading near the lower end of its 52-week range, and InvestingPro analysis suggests it is undervalued with strong financial health.
American Century and Stowers Institute Reveal 12% Stake in Enovis Corporation
American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have jointly reported a 12.0% beneficial ownership in Enovis Corporation, as detailed in an SEC filing on November 16, 2026. This stake, totaling 6,889,905 shares, highlights their significant investment in the company. The filing clarifies the corporate structure, with American Century Investment Management being a subsidiary of American Century Companies, controlled by the Stowers Institute, and confirms that these securities were acquired in the ordinary course of business without intent to influence control.
Form 4 Enovis Corp: Angela S. Lalor (Director) For: 12 November
This article reports on a Form 4 filing for Enovis Corp, detailing a transaction made by Angela S. Lalor, a Director, on November 12th. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's stock by its insiders. The article indicates that this information was published on November 16, 2026, at 09:36 p.m.
Enovis director Angela Lalor buys $49,386 in company stock By Investing.com
Enovis director Angela Lalor recently purchased 1,754 shares of the company's common stock for a total of $49,386 through open market transactions on November 12 and 13, 2026. These purchases occurred while the stock was trading near the lower end of its 52-week range. InvestingPro analysis suggests Enovis (NASDAQ:ENOV) is undervalued with "GOOD" financial health and strong recent momentum.
Three direct purchases at Enovis (ENOV): director Angela S. Lalor buys 1,754 shares.
Enovis (ENOV) director Angela S. Lalor made three direct purchases of the company's common stock, acquiring a total of 1,754 shares. These transactions occurred on November 12 and November 13, 2026, with shares purchased at weighted average prices ranging from $27.71 to $28.29. Following these purchases, Lalor's direct holdings in Enovis increased to 34,997 shares.
Three linked entities report the same Enovis (ENOV) stake, not three separate holdings.
American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have each reported a 12.0% passive stake in Enovis Corporation (ENOV), totaling 6,889,905 common shares. These are overlapping reports of the same position, not additive holdings, as American Century Investment Management is a subsidiary of American Century Companies, which is controlled by Stowers Institute. The entities collectively hold sole voting power over 6,634,176 shares and sole dispositive power over all 6,889,905 shares.
Form 4 Enovis Corp: Angela S. Lalor (Director) For: 10 November
This article reports on a Form 4 filing for Enovis Corp, indicating that Director Angela S. Lalor was involved in a transaction on November 10th. The filing provides details on insider trading activity for the company. The article also mentions Enovis Corp's stock symbol ENOV and its recent price performance.
Form 4 Enovis Corp: Sharon L. Wienbar (Director) For: 10 November By Investing.com
This article reports on a Form 4 filing for Enovis Corp, indicating an insider transaction by Director Sharon L. Wienbar. The filing date mentioned is November 10. The content primarily serves as an announcement for this regulatory disclosure without providing further details on the transaction itself.
Enovis (ENOV) director buys shares at $28.28 and $28.86.
Enovis Corporation director Angela S. Lalor reported direct purchases of 1,757 shares of ENOV stock across two transactions. On November 10, 2026, she bought 887 shares at a weighted-average price of $28.28, and on November 11, 2026, she purchased 870 shares at $28.86. These transactions increased her direct holdings to 33,243 shares.
At $28.43 a share, Enovis (ENOV) director Sharon L. Wienbar reports buying 874 shares.
Enovis Corp. director Sharon L. Wienbar reported two direct purchases of company stock: 900 shares on November 11, 2026, at a weighted-average price of $27.76, and 874 shares on November 10, 2026, at $28.43. While the November 11 transaction was reported as a purchase, an attached note clarified it represented multiple sales within a price range, which can cause discrepancies in the reported insider activity. These transactions increased Wienbar's direct holdings to 45,551 shares.
Enovis to present at Jefferies Global Healthcare Conference in London on Nov 17, 2026.
Enovis Corporation announced its management team will present at the Annual Jefferies Global Healthcare Conference in London on November 17, 2026. The presentation, accessible via live audio webcast and replay, will allow Enovis to showcase its innovations and growth strategy to investors. The article also provides a brief overview of health-sector market data, noting recent movements in several US stocks.
Director Sharon L. Wienbar Acquires 1,831 Shares of Enovis Corporation in Two Open-Market Transactions
Enovis Corporation Director Sharon L. Wienbar recently acquired 1,831 shares of the company's common stock through two open-market transactions on November 6 and November 9, 2026. These purchases increased her direct ownership to 43,777 shares. The transactions, reported via a Form 4 to the SEC on November 10, 2026, were executed at prices of $27.55 and $26.98 per share, respectively.
Enovis director Sharon Wienbar buys $49,917 of company stock By Investing.com
Enovis Corp. director Sharon L. Wienbar recently purchased $49,917 worth of company stock through open market transactions on November 6 and November 9, 2026. These insider buys occurred as Enovis stock demonstrated strong momentum, rising 15.6% over the past week and trading at $28.22, with InvestingPro analysis indicating the stock is undervalued and expected to be profitable this year. The company also recently reported strong third-quarter results, surpassing revenue and profit forecasts, and received a raised price target from BTIG.
Director buys Enovis (ENOV) shares at $27.55 and $26.98 in two purchases.
Enovis Corp director Sharon L. Wienbar made two direct purchases of the company's common stock. She bought 907 shares at $27.55 per share on November 6, 2026, and an additional 924 shares at $26.98 per share on November 9, 2026. These transactions increased her direct holdings in the company from 41,946 to 43,777 shares.
Form 4 Enovis Corp: Sharon L. Wienbar (Director) For: 6 November
This article reports on a Form 4 filing for Enovis Corp, indicating an insider transaction by Director Sharon L. Wienbar on November 6. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of securities by a company's officers, directors, and principal stockholders. Such disclosures offer transparency into insider trading activities.
Form 4 Enovis CORP For: Nov 06 Filed by: Wienbar Sharon L
This Form 4 filing details insider transactions for Enovis CORP (ENOV) by Director Sharon L. Wienbar. The report indicates that Wienbar acquired shares of common stock on November 6 and November 9, 2026, through open market purchases. These transactions increased her direct beneficial ownership of the company's common stock.
Enovis (NYSE:ENOV) Q3 2026: Recon Growth, Guidance Raised
Enovis (NYSE:ENOV) reported strong Q3 2026 results, with sales growth on both reported and organic bases, driven by significant market share gains in its Reconstructive segment. The company also raised its full-year guidance for adjusted EBITDA and adjusted EPS, reflecting confidence in margin improvement and successful execution of its innovation-led strategy. This performance highlights Enovis's ability to capitalize on steady demand from an aging population and advancements in orthopedic medical technology.
Enovis director Sharon Wienbar buys $49,917 of company stock By Investing.com
Enovis Corp. director Sharon L. Wienbar recently purchased $49,917 worth of company stock through open market transactions on November 6 and November 9, 2026. Following these purchases, Wienbar directly holds 43,777 shares. The insider activity coincides with Enovis stock showing strong momentum, up 15.6% over the past week, and being identified as undervalued by InvestingPro analysis, with analysts predicting profitability and net income growth for the year.
CCORF Maintains Enovis Corp(ENOV.US) With Buy Rating, Cuts Target Price to $42
CCORF has reiterated its Buy rating for Enovis Corp (ENOV.US) while simultaneously reducing its target price to $42. This update reflects the firm's ongoing positive outlook on the company despite a revised valuation.
Enovis Stock Earnings Beat Spurs New $200 Million Buyback Plan
Enovis reported strong third-quarter 2026 results, returning to profitability and exceeding sales expectations. The company also announced a new $200 million share repurchase authorization, signaling confidence in its financial health and operational improvements. This move aims to enhance per-share metrics and reshape the company's earnings profile following a period of stock decline.
Enovis Corporation (E2NO34.SA) stock price, news, quote and history
Enovis Corporation (E2NO34.SA) stock is currently priced at 38.16 with no change, based on delayed quotes from São Paulo. The company, a medical technology firm, specializes in developing solutions across two segments: Prevention and Recovery, and Reconstructive. Financial data indicates a market cap of 2.202B and a trailing 12-month EPS of -48.16.
Enovis (ENOV) Shares Just Moved, So What Is Catching Attention?
Enovis (ENOV) recently reported strong Q3 2026 results, moving from a significant loss to a small profit and announcing a US$200 million share repurchase program. This news has led to a sharp increase in share price, with a 1-day return of 17.2%. Despite recent gains, the company's long-term shareholder returns remain challenging, indicating a mixed picture for investors.
BTIG raises Enovis stock price target to $42 on solid execution
BTIG has increased its price target for Enovis Corp (NYSE:ENOV) to $42 from $36, maintaining a Buy rating after the company's solid third-quarter performance. Enovis's Q3 revenue of $558.7 million slightly missed BTIG's estimate but beat consensus, leading to raised full-year adjusted EBITDA and EPS guidance, and a new $200 million share buyback program. The company appears undervalued, and future growth is expected from strategic acquisitions and product developments.
Enovis earnings beat by $0.11, revenue topped estimates
Enovis (NYSE: ENOV) reported stronger-than-expected third-quarter earnings per share of $0.88, surpassing analyst estimates by $0.11. The company's revenue also exceeded expectations, coming in at $558.72 million against a consensus of $557.14 million. Enovis provided FY 2026 guidance, projecting EPS between $3.52-$3.73 and revenue between $2.32B-$2.35B.
Enovis Q3 2026 Earnings Call Transcript
Enovis reported strong third-quarter 2026 results, with sales up 2% year-over-year to $559 million and organic growth of 5%, driven by Recon and PNR segments. The company is set to acquire Essential Robotics by year-end, aiming to introduce knee and shoulder robots within two years, and has authorized a $200 million share repurchase program. Enovis raised its full-year guidance for adjusted EPS to between $3.58 and $3.79 and expects revenue in the range of $2.32 to $2.35 billion, with approximately 5% organic growth.
ENOV: Enovis Corporation filed SEC Form 8-K: Results of Operations...
Enovis Corporation (ENOV) filed an SEC Form 8-K reporting Q3 2026 net sales of $559 million, a 2% reported and 5% organic increase. The company raised its full-year adjusted EBITDA and adjusted EPS guidance, and its board approved a new $200 million share repurchase authorization. This information suggests a bullish outlook, despite a slight narrowing of revenue guidance and a decline in Prosthetics and Restorative sales.
Enovis Corporation Announces Q3 2026 Net Sales of $558.7 Million and Positive Operating Income
Enovis Corporation reported net sales of $558.7 million for Q3 2026, an increase from the previous year, and returned to operating profitability with $3.4 million in operating income. This marks a significant improvement from the prior year's operating loss due to a large goodwill impairment charge. The company also reduced its long-term debt and reported a net income attributable to Enovis Corporation of $3.1 million for the quarter.
Earnings Preview: Enovis Corp to Report Financial Results Pre-market on November 05
Enovis Corp (NYSE: ENOV) is scheduled to report its financial results pre-market on November 05. The article provides a detailed preview of analyst expectations, including estimated earnings per share (EPS) and revenue figures, and examines the company's past performance against these estimates. It also covers recent analyst ratings and price targets, offering insight into market sentiment and potential stock movement.
Enovis Corporation (ENOV) Stock forecasts
Argus has raised its target price for Enovis Corporation (ENOV) stock to $20.00. Enovis Corp is a medical technology company providing devices and services for patient care, from injury prevention to rehabilitation. The current price for ENOV is $21.08.
Enovis Corp (C520.SG) valuation measures and financial statistics
This article provides detailed valuation measures and financial statistics for Enovis Corp (C520.SG). It includes current and historical data for market capitalization, enterprise value, various P/E ratios, and price-to-sales. The report also covers key financial highlights, management effectiveness, balance sheet items, cash flow, and trading information like stock price history and share statistics.
CFX5924786 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Enovis Corporation's CFX5924786 bond. It outlines key facts such as the issuer, issue and maturity dates, face value, and minimum denomination. The profile also details the bond's interest payment structure, including the semi-annual fixed rate coupon, and upcoming payment schedule, along with redemption information.
Enovis Corporation (ENOV) Stock forecasts
Argus has lowered its target price for Enovis Corporation (ENOV) to $17.00, while the current stock price is $19.59. Enovis Corp is described as a medical technology company providing devices and services for patient care, from injury prevention to joint replacement and rehabilitation. The report was published on October 7, 2026.
Enovis Is Maintained at Buy by Needham
Needham has reiterated its Buy rating on Enovis, a medical technology company. The analyst's decision indicates continued confidence in the company's prospects. This report provides an overview of recent analyst ratings and price targets for Enovis.
Needham Cuts Price Target on Enovis to $34 From $52, Keeps Buy Rating
Needham has revised its price target for Enovis (ENOV) shares down to $34 from $52, while maintaining a Buy rating on the stock. This adjustment comes after other firms like BofA Securities and BMO Capital also recently modified their price targets for the medical technology company. Enovis, which specializes in reconstructive surgery, rehabilitation, and pain management products, also recently announced plans to acquire eCential Robotics.
Needham cuts Enovis stock price target on robotics deal impact
Needham has lowered its price target for Enovis Corp (NYSE: ENOV) from $52 to $34, while maintaining a Buy rating, due to the anticipated impact of its acquisition of eCential Robotics. This deal is expected to create near-term margin pressure, reducing Enovis’s adjusted EBITDA margin by approximately 150 basis points in 2027, partially offset by underlying improvements. Other analysts like UBS, BMO Capital, and Citizens have also adjusted their price targets for Enovis following the acquisition announcement.
Needham cuts Enovis stock price target on robotics deal impact By Investing.com
Needham has lowered its price target for Enovis Corp (NYSE: ENOV) from $52 to $34, while maintaining a Buy rating. This adjustment follows Enovis's anticipated acquisition of eCential Robotics, which is expected to negatively impact the company's adjusted EBITDA margin by approximately 150 basis points in 2027. Despite the short-term margin pressures, analysts maintain a Strong Buy consensus, with InvestingPro suggesting the stock is currently undervalued.
Enovis (ENOV), Why Is Fresh Attention Building Now?
Enovis (ENOV) is garnering fresh attention as its upcoming investor call on November 5, 2026, approaches, set to review third-quarter results. Despite recent share price weakness, with a 40.4% drop over the last year, analysts suggest the stock is 54% undervalued, estimating a fair value around $38.33. This valuation is driven by an expanding orthopedic market, Enovis's focus on innovative technologies, and projected earnings growth from a current loss to a profit by 2029, though significant forecast dispersion exists.
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
Enovis Corporation (NYSE: ENOV) announced it will release its third-quarter 2026 financial results on Tuesday, November 4th, 2026. The company will then host a conference call on Wednesday, November 5th, 2026, at 8:30 AM ET to discuss these results. A live webcast and replay will be available on the company's investor relations website.
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
Enovis Corporation (NYSE: ENOV) announced it will host an investor conference call and live webcast on Thursday, November 5th, 2026, at 8:30 a.m. Eastern Time to discuss its third-quarter 2026 financial results. The company will issue an earnings press release earlier that morning, with webcast and presentation details available on its investor relations website.
Enovis Corporation (ENOV) Stock forecasts
This page appears to be an error page or a page with broken content from Yahoo Finance. It contains navigation links, market data for various indices and cryptocurrencies, and boilerplate footer information, but lacks actual article content regarding Enovis Corporation (ENOV) stock forecasts. The page indicates an error in retrieving data.
Enovis stock hits 52-week low at 17.29 USD By Investing.com
Enovis Corp (NYSE: ENOV) stock recently hit a 52-week low of $17.29, representing a 44.66% decline over the past year. Despite this, InvestingPro analysis suggests the stock may be undervalued, with analysts predicting profitability in 2026 and price targets ranging from $24 to $52. Recent news includes Enovis surpassing Q2 2026 earnings estimates and acquiring eCential Robotics for approximately $205 million, though analyst price targets have been adjusted due to potential margin impacts from the acquisition.
Enovis stock hits 52-week low at 17.29 USD By Investing.com
Enovis Corporation (ENOV) stock recently hit a 52-week low of $17.29, reflecting a 44.66% decline over the past year. Despite this, InvestingPro analysis suggests the stock may be undervalued, with analysts setting price targets between $24 and $52, and net income is projected to grow this year with profitability expected in 2026. Recent news includes Enovis' acquisition of eCential Robotics for approximately €176 million, which has led analysts like UBS, BMO Capital, and Citizens to adjust their price targets, primarily due to concerns over potential margin dilution.
Enovis stock hits 52-week low at 17.29 USD
Enovis (ENOV) stock recently hit a 52-week low of $17.29, reflecting a 44.66% decline over the past year. Despite this, InvestingPro analysis suggests the stock may be undervalued, with analysts predicting profitability in 2026 and price targets ranging from $24 to $52. Recent news includes Enovis's Q2 2026 adjusted earnings surpassing estimates and its acquisition of eCential Robotics, which has led to revised price targets from analysts due to potential margin impacts.
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
Enovis Corporation (NYSE: ENOV) announced it will host an investor conference call and live webcast on November 5th, 2026, at 8:30 a.m. Eastern Time to discuss its third quarter 2026 financial results. An earnings press release will be issued earlier that morning. The webcast and presentation will be available on the "Investors" section of Enovis' website.
Transcript: Enovis Q2 2026 Earnings Conference Call
Enovis reported strong Q2 2026 results with 5% organic growth, driven by its Recon and P&R segments. The company highlighted the successful commercial launch of Arvis and continued innovation, while reaffirming its full-year guidance despite expected Q3 seasonality and ongoing geopolitical impacts. Management emphasized improved financial discipline, with significant free cash flow generation and debt reduction.
BofA Securities Adjusts Enovis Price Target to $44 From $51, Maintains Buy Rating
BofA Securities has lowered its price target for Enovis (ENOV) to $44 from $51 but has reiterated a Buy rating on the stock. This adjustment comes despite the company having an average analyst rating of "buy" and a mean price target of $41.58.
UBS cuts Enovis stock price target on acquisition impact
UBS has lowered its price target for Enovis Corp (NYSE:ENOV) to $44 from $51, while maintaining a Buy rating. This adjustment reflects the impact of Enovis's recent acquisition of eCential Robotics and broader seasonality dynamics, with management anticipating deal-related dilution to 2027 adjusted EBITDA margins. Despite a 44.5% stock drop over the past year, InvestingPro analysis suggests the stock is undervalued, and other analysts like BMO Capital and Citizens have also adjusted their targets following the acquisition news.
UBS cuts Enovis stock price target on acquisition impact By Investing.com
UBS has lowered its price target for Enovis Corp (NYSE:ENOV) from $51 to $44, while maintaining a Buy rating. This adjustment reflects the anticipated impact of Enovis's recent acquisition of eCential Robotics and broader seasonal dynamics, which are expected to cause deal-related dilution to 2027 adjusted EBITDA margins. Despite the reduced price target, the stock shows a potential upside of over 138% from its current trading price and is considered undervalued by InvestingPro analysis.
UBS cuts Enovis stock price target on acquisition impact By Investing.com
UBS has lowered its price target for Enovis Corp (NYSE:ENOV) from $51 to $44, while maintaining a Buy rating. This adjustment reflects the impact of Enovis's recent acquisition of eCential Robotics and broader seasonality, which is expected to dilute 2027 adjusted EBITDA margins by 150 basis points. Despite the near-term headwinds, UBS projects a return to year-over-year margin improvement in 2028, and InvestingPro analysis suggests the stock is currently undervalued.
BofA Securities Adjusts Enovis Price Target to $44 From $51, Maintains Buy Rating
BofA Securities has lowered its price target for Enovis (ENOV) to $44 from $51, while reiterating a "Buy" rating on the medical technology company's stock. This adjustment reflects a revised valuation perspective but indicates continued confidence in the company's prospects. Enovis, which specializes in reconstructive surgery, rehabilitation, and pain management products, closed at $18.69 on October 5th.